thoracic oncology research initiative 

TORI brings together investigators from multiple departments and centers across the campus, including Medicine, Pharmacology, Immunology, Pathology, Biochemistry and Molecular Genetics, the School of Dental Medicine and the School of Public Health. Major areas of strength in lung cancer research include characterization and treatment of preneoplastic lesions, targeted therapies against oncogenic tyrosine kinase drivers, and determinants of response to immunotherapy. 

selected publications

Zhong H, Lu W, Tang Y, Wiel C, Wei Y, Cao J, Riedlinger G, Papagiannakopoulos T, Guo JY, Bergo MO, Kang Y, Ganesan S, Sabaawy HE, Pine SR. SOX9 drives KRAS-induced lung adenocarcinoma progression and suppresses anti-tumor immunity. Oncogene. 2023 Jun;42(27):2183-2194. doi: 10.1038/s41388-023-02715-5. Epub 2023 May 31. PMID: 37258742.

Bhatt V, Lan T, Wang W, Kong J, Lopes EC, Wang J, Khayati K, Raju A, Rangel M, Lopez E, Hu ZS, Luo X, Su X, Malhotra J, Hu W, Pine SR, White E, Guo JY. Inhibition of autophagy and MEK promotes ferroptosis in Lkb1-deficient Kras-driven lung tumors. Cell Death Dis. 2023 Jan 26;14(1):61. doi: 10.1038/s41419-023-05592-8. PMID: 36702816; PMCID: PMC9879981.

Kwon M, Rubio G, Wang H, Riedlinger G, Adem A, Zhong H, Slegowski D, Post-Zwicker L, Chidananda A, Schrump DS, Pine SR, Libutti SK. Smoking-associated Downregulation of FILIP1L Enhances Lung Adenocarcinoma Progression Through Mucin Production, Inflammation, and Fibrosis. Cancer Res Commun. 2022 Oct 18;2(10):1197-1213. doi: 10.1158/2767-9764.CRC-22-0233. PMID: 36860703; PMCID: PMC9973389.

CMS Login